| Study | Reason for exclusion |
|---|---|
| ACCEPT‐D | This study studied the effects of aspirin and simvastatin combination |
| AFCAPS/TexCAPS | The intervention in treatment group is diet and lovastatin, and the intervention in control group is diet |
| AIM‐HIGH | All participants received simvastatin (or simvastatin plus ezetimibe) at a dose sufficient to maintain LDL‐ cholesterol. Participants were randomised to extended‐release niacin or matching placebo |
| ASTRONOMER | This study did not report the VTE relevant outcomes |
| Caramelli 2002 | This study did not report the VTE relevant outcome |
| CARDS | This study did not report the VTE relevant outcomes |
| ChiCTR‐TNRC‐08000263 | Non‐randomised control study |
| DECREASE III | This study did not report the VTE relevant outcomes |
| Doggen 2004 | Case‐control study |
| ELIMIT | A total of 102 patients were randomised to either mono‐therapy with simvastatin (40 mg daily) or triple‐therapy with simvastatin (40 mg daily), ER niacin (1500 mg daily), and ezetimibe (10 mg daily). This study did not report the VTE relevant outcomes |
| Ge 2011 | This study did not report the VTE relevant outcomes |
| Haak 2001 | This study did not report the VTE relevant outcomes |
| HERS | Cohort study |
| HPS2‐THRIVE | This study compared ER niacin 2 g plus laropiprant 40 mg daily with placebo for occlusive arterial disease. This study did not report the VTE relevant outcomes |
| Huerta 2007 | Case‐control study |
| Jeong 2013 | This study did not report the VTE relevant outcomes |
| Lacut 2004 | Case‐control study |
| Lacut 2008 | Case‐control study |
| LEADe | Mild to moderate Alzheimer's disease patients were receiving donepezil |
| Liu 2011 | This study did not report the VTE relevant outcomes |
| MEGA | This study did not report the VTE relevant outcomes |
| METEOR | This study did not report the VTE relevant outcomes |
| NCT00437892 | This study evaluated adult patients with a single episode of idiopathic VTE (either DVT or PE) who received at least 6 months of adequate treatment with oral anticoagulants, for whom treatment withdrawal is planned, and with LDL cholesterol levels of equal to or greater than 130 mg/dL, not evaluating the patients at risk of VTE |
| PROCEDURE | This is a study protocol and does not report on the relevant VTE outcomes |
| PROSPER | Case control study |
| Ramcharan 2009 | Case‐control study |
| RATIONAL | This study did not report the VTE relevant outcomes |
| Ray 2001a | Cohort study |
| Rosen 2013 | This study compared switching to ezetimibe/simvastatin (EZ/S) 10/20 mg with doubling the run‐in statin dose (to simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg in subjects with cardiovascular disease (CVD) and diabetes and did not report the VTE relevant outcomes |
| Shai 2014 | Case‐control study |
| Smeeth 2009 | Cohort study |
| Stangier 2009 | Authors focused on pharmacokinetics and pharmacodynamics, and did not mention all the outcomes we evaluated |
| Sørensen 2009 | Case‐control study |
| van der Loo 2011 | This study did not report the VTE relevant outcomes |
| West 2010 | This study compared simvastatin with simvastatin plus ezetimibe and did not report the VTE relevant outcomes |
| Yang 2002 | Cohort study |
DVT: deep vein thrombosis ER: extended release LDL: low density lipoprotein PE: pulmonary embolism VTE: venous thromboembolism